Podcast
Episode 9 of BioByteas by Windsor Bux welcomes Axel Hoos, MD, PhD – Chief Executive Officer
Dr. Axel Hoos, a physician and scientist with broad experience in drug development and building life science organizations, shares his insights and experiences in the biopharma industry. Dr. Hoos highlights the significance of patient focus, excellence in execution, and resilience in achieving success in drug development. He also emphasizes the importance of building the right team and creating a culture that enables high performance. Additionally, Dr. Hoos shares examples of setbacks and challenges he has faced throughout his career and provides advice for emerging biotech entrepreneurs on scaling their companies and attracting investments.
Takeaways
- Patient focus, excellence in execution, and resilience are key to success in drug development.
- Building the right team and creating a high-performance culture are crucial for achieving goals.
- Setbacks and challenges are common in the biopharma industry, but having a clear vision and the ability to execute can lead to success.
- Following the science, allocating capital effectively, and being realistic about what is achievable are important for scaling biotech companies and attracting investments.ry.
You can also listen to this podcast on Spotify:
Welcome to BioBytes – Windsor Bux, where we bring you exclusive interviews with the movers and shakers of the biotech and pharmaceutical industry. Join us as we delve into the experiences and valuable insights of leading executives, exploring how they’re shaping the future and making a difference. Get ready for compelling conversations that will expand your knowledge and inspire your own journey in this exciting field!
- Shehnaaz Suliman, M.D, CEO at ReCode Therapeutics
- Sandy Milligan, MD JD, C-Suite Executive & Board Member
- Alex Oshmyansky, MD, PhD, CEO / Co-Founder
- Derek Adams, CEO & President
- Jason Cole – CEO & Chair of the Board, SalioGen
- David Donabedian, PhD – Executive Partner, Interim NewCo CEO, Longwood Fund
- Stephanie Oestreich, PhD, MPA Managing Director at Myeloma Investment Fund
- Ronan O’Hagan, Chief Executive Officer
- Alison Schecter, MD, CMO/CEO
- Joe Foster – Reebok, Founder